The Personalized Medicine Coalition announced that Daryl Pritchard will be its new VP of science policy, in charge of promoting the organization's science-related policies and of raising awareness of precision healthcare issues among policymakers, providers, and patients. Before joining PMC, Pritchard was director of policy research at the National Pharmaceutical Council; director of research programs advocacy and personalized medicine at the Biotechnology Industry Organization; and the director of government affairs for the American Association for Dental Research.
The US Food and Drug Administration has promoted Grail Sipes as its permanent director of the Office of Regulatory Policy (ORP). Sipes bring two decades of experience as a laywer to the new position that she will assume on Sept. 22.
Grail joined FDA's Center for Drug Evaluation and Research in 2011 as senior regulatory counsel for ORP. Before that Grail was a partner with Covington & Burling, where she was part of the Food and Drug Practice Group, as well as the Life Sciences Industry Group.
Adaptive Biotechnologies has appointed Brian Hansen as its chief commercial officer, responsible for overseeing the firm's sales, customer relations, marketing, billing, and reimbursement efforts. Hansen joins Adaptive from Novartis subsidiary Genoptix where he was senior VP of global sales and service.
Trovagene has appointed cancer genetics pioneer Alberto Bardelli to its scientific advisory board. Bardelli was among the first researchers to identify mutations in kinase genes linked to colorectal cancer and other tumors. Currently, Bardelli is director of the Laboratory of Molecular Genetics at the Institute for Cancer Research and Treatment and an association professor in the oncology department at the Torino Medical School in Candiolo, Italy. He also cofounded the biotechnology firm Horizon Discovery Group.
Veracyte has promoted Christopher Hall to COO, the company announced. Hall joined the firm in 2010 as chief commercial officer.